Meeting Brief: The 2nd Annual John Fitzpatrick Prostate Cancer Conference 2016

Members of the Atturos team attended the 2nd Annual John Fitzpatrick Prostate Cancer Conference last week in the Aviva Stadium in Dublin. CEO Stephen Pennington and Director of Operations Fergus Fleming were joined by members of Steve’s Biomedical Proteomics academic group. The team heard research updates from urology specialists from various complementary disciplines around the world.

Stacy Loeb’s talk about Smarter Prostate Cancer Screening and Detection was a logical first step to introduce the Diagnostics-themed first session. Citing NCCN guidelines for biopsy indications she remarked that combinations of multiple markers can improve their predictive value. Our own Director of Clinical Affairs Stephen Finn was next and warned about more rigorous exercise interventions are on the way for participants of the Movember GAP study, and Jelle Barentsz in the first of his talks discussed the use of multi-parametric MRI in prostate cancer detection. Jeremy Clark, who had spoken at the UCD Conway Institute the day before, opened the Emerging Biomarkers discussion by introducing the use of RNA probes for detecting biomarkers in urine.

Michael Blute spoke about the impact of PSA and was cautious about the “all or nothing” approach to its use as screening tool. David Galvin spoke about IPCOR and their patient-centered approach to delivering appropriate care, while John Armstrong seconded the need for teamwork and a multidisciplinary approach to research, and highlighted disparities between cancer care in locations around the UK in their presentations.

The closing panel discussion was chaired by Paul Sweeney, and all involved insisted on learning more about the patient’s condition before making rash decisions about the best treatment options. The differences in opinions from key opinion leaders about treatment decisions highlights the need for further collaboration among multidisciplinary teams to provide as much relevant information about each patient’s case when making treatment decisions. One thing everyone agreed on was the patient focussed approach to information sharing and in-depth discussion about treatment options.

Further work from Gerard Morton, Paul Cathcart, John Kelly, Robert Nadler, Peter Hoskin, Chris Sweeney, Sue Slovin, Emmanuel Antonarakis, and David Waugh rounded out the interdisciplinary meeting’s roster. A detailed meeting summary has been featured in Oncology News.